82
Participants
Start Date
November 27, 2015
Primary Completion Date
October 15, 2019
Study Completion Date
October 15, 2019
Furosemide Cohort 1
furosemide 1 mg/kg q 24 hours IV or 2 mg/kg q 24 hours enterally Cohorts will be enrolled sequentially after a safety review.
Furosemide Cohort 2
furosemide 1 mg/kg q 6 hours IV or 2 mg/kg q 6 hours enterally Cohorts will be enrolled sequentially after a safety review.
Furosemide Cohort 3
furosemide 2 mg/kg q 6 hours IV or 4 mg/kg q 6 hours enterally Cohorts will be enrolled sequentially after a safety review.
Placebo
Sugar water will be administered in a equivalent volume as drug intervention.
Virginia Commonwealth University, Richmond
West Virginia University, Morgantown
New Hanover Regional Medical Center, Wilmington
University of Florida Jacskonville Shands Medical Center, Jacksonville
Wolfson Children's Hospital, Jacksonville
South Miami Hospital, South Miami
John's Hopkins Al Children's Hospital, St. Petersburg
University of Kentucky Medical Center, Lexington
Nationwide Children's Hospital/The Ohio State University, Columbus
MetroHealth Medical Center, Cleveland
University of Illinois at Chicago, Chicago
Children's Mercy Hospital and Clinics, Kansas City
Wesley Medical Center, Wichita
Arkansas Children's Hospital/University of Arkansas for Medical Sciences, Little Rock
University of Oklahoma Health Sciences Center, Oklahoma City
University Medical Center of Southern Nevada, Las Vegas
Loma Linda University Medical Center, Loma Linda
Floating Hospital for Children at Tufts Medical Center, Boston
UMass Memorial Medical Center, Worcester
University of Michigan Medical Center, Ann Arbor
The University of North Carolina at Chapel Hill/North Carolina Children's Hospital, Chapel Hill
Collaborators (1)
Duke University
OTHER
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
The Emmes Company, LLC
INDUSTRY
University of North Carolina, Chapel Hill
OTHER